IDEAYA Biosciences: Trading Near a Two-Year High While the Model Flags a Sell

IDEAYA Biosciences trades at $38.84, within a few percent of its two-year high of $40.11, after a long climb from a two-year low of $14.71. Price momentum and fundamentals are pointing in opposite directions here: our scoring model rates Quality at 25/100 and Opportunity at 19/100, and the Recommendation score of 34/100 produces a Sell signal. This IDEAYA Biosciences, Inc. stock analysis explains why a stock near the top of its range still scores poorly on the underlying business metrics.

What Is Happening With the Stock Price

At $38.84, IDEAYA sits in the upper end of its two-year range of $14.71 to $40.11, about 95% of the way up that band and only around 3% below the two-year high. The stock has more than doubled off its low over the period, so a buyer today is entering after a large advance rather than during a pullback. Market capitalisation is $3.75B against trailing revenue of $234M, an EV/Revenue multiple of about 13. For a clinical-stage biotechnology company, the share price is driven mainly by expectations for the drug pipeline rather than by current financial results, which magnifies both the upside on good news and the downside on setbacks.

Quality: Is This a Financially Sound Business?

Quality scores 25/100, the weakest of the three pillars. The profitability figures are stark: gross margin is -36.4%, operating margin is -1380.7%, and net margin is -74.8%. A negative gross margin is unusual and most likely reflects that IDEAYA’s reported revenue is largely collaboration or milestone payments, with associated costs booked against them, rather than product sales with a normal cost structure. The extreme operating margin is a function of a small revenue base sitting beneath a much larger research budget. Return on equity is -16.2% and return on assets is -11.5%. The clear strength is the balance sheet: debt-to-equity is just 0.02, and the current and quick ratios are both above 10, pointing to a large cash position relative to near-term obligations. Free cash flow was -$71M over the trailing twelve months, a modest burn next to that liquidity.

Growth: Does This Company Have Real Upside?

Growth scores 58/100, the best of the three. The five-year revenue CAGR is 62.5%, though that builds off a small base and the figures can be lumpy for a company whose revenue depends on partnership milestones. A trailing-twelve-month revenue growth rate is not available in the data, so the recent trend cannot be confirmed from these numbers, and earnings growth is not meaningful because the company is unprofitable. EV/Revenue of about 13 and a negative EV/EBITDA of -14.22, the result of negative EBITDA, mean the valuation is not supported by current cash generation. For this IDEAYA Biosciences, Inc. stock analysis, the growth score rests on the long-run revenue trajectory and the scale of the opportunity implied by the pipeline, not on proven, repeatable sales.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 19/100. There is no P/E ratio because earnings are negative, so valuation leans on price-to-book of 3.12 and EV/Revenue near 13, both of which look full for a business that is not yet profitable. The bigger issue for entry timing is price position: at roughly 95% of the way up its two-year range, the stock is close to its high, so an investor is paying near the top of the band. A rich valuation combined with a near-high price is what holds the entry-timing score down.

IDEAYA Biosciences, Inc. Stock Analysis: The Bottom Line

To close this IDEAYA Biosciences, Inc. stock analysis, the case in the stock’s favour is a 62.5% five-year revenue growth rate, almost no debt, and a cash cushion large enough to fund operations through a meaningful stretch of clinical work. The case against, and the reason the model lands on Sell, is a -36.4% gross margin, an operating margin below -1000%, a valuation around 13 times revenue, and a share price sitting near a two-year high. The main risk is that a pipeline setback or a need to raise fresh capital would fall on a stock that has already priced in a lot of success; the offsetting possibility is that positive clinical or partnership news could extend the run despite weak current fundamentals. The Buy, Hold, and Sell labels here reflect a transparent quantitative model, not personalised advice, and a Sell signal is a prompt for further research rather than a call to transact.